PODD Key Statistics, Chart & Performance
The current stock price of PODD is 243.15 USD. In the past month the price decreased by -18.73%. In the past year, price decreased by -14.11%.
PODD Technical Analysis
PODD Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to PODD. PODD has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
PODD Financial Highlights
Over the last trailing twelve months PODD reported a non-GAAP Earnings per Share(EPS) of 4.57. The EPS increased by 27.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 9.76% | ||
| ROA | 8.13% | ||
| ROE | 17.79% | ||
| Debt/Equity | 0.68 |
PODD Forecast & Estimates
34 analysts have analysed PODD and the average price target is 383.36 USD. This implies a price increase of 57.66% is expected in the next year compared to the current price of 243.15.
For the next year, analysts expect an EPS growth of 49.49% and a revenue growth 30.95% for PODD
PODD Ownership
PODD Latest News, Press Relases and Analysis
PODD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.02 | 188.146B | ||
| ISRG | INTUITIVE SURGICAL INC | 47.95 | 169.625B | ||
| SYK | STRYKER CORP | 23.97 | 137.924B | ||
| BSX | BOSTON SCIENTIFIC CORP | 22.17 | 111.924B | ||
| BDX | BECTON DICKINSON AND CO | 13.75 | 59.33B | ||
| IDXX | IDEXX LABORATORIES INC | 43.44 | 51.339B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.38 | 46.291B | ||
| RMD | RESMED INC | 21.75 | 38.394B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.39 | 37.64B | ||
| DXCM | DEXCOM INC | 27.76 | 27.621B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PODD
Company Profile
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 3,900 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Company Info
INSULET CORP
100 Nagog Park
Acton MASSACHUSETTS 01720 US
CEO: Shacey Petrovic
Employees: 3900
Phone: 19786007000
INSULET CORP / PODD FAQ
Can you describe the business of INSULET CORP?
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 3,900 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
What is the current price of PODD stock?
The current stock price of PODD is 243.15 USD. The price decreased by -3.22% in the last trading session.
Does INSULET CORP pay dividends?
PODD does not pay a dividend.
How is the ChartMill rating for INSULET CORP?
PODD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What sector and industry does INSULET CORP belong to?
INSULET CORP (PODD) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Can you provide the ownership details for PODD stock?
You can find the ownership structure of INSULET CORP (PODD) on the Ownership tab.